158 related articles for article (PubMed ID: 36889765)
21. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
[TBL] [Abstract][Full Text] [Related]
22. Exceptional response to everolimus in a novel tuberous sclerosis complex-2 mutation-associated metastatic renal-cell carcinoma.
Alsidawi S; Kasi PM
Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610387
[TBL] [Abstract][Full Text] [Related]
23. Sclerosing TSC1 mutated renal cell carcinoma: An unusual pattern mimicking MITF family translocation renal cell carcinoma.
Williamson SR; Cardili L; Whiteley LJ; Sanchez J; Kis O
Genes Chromosomes Cancer; 2020 Oct; 59(10):591-594. PubMed ID: 32418252
[TBL] [Abstract][Full Text] [Related]
24. Eosinophilic vacuolated tumor (EVT) of kidney demonstrates sporadic TSC/MTOR mutations: next-generation sequencing multi-institutional study of 19 cases.
Farcaş M; Gatalica Z; Trpkov K; Swensen J; Zhou M; Alaghehbandan R; Williamson SR; Magi-Galluzzi C; Gill AJ; Tretiakova M; Lopez JI; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Siadat F; Sangoi A; Gao Y; Ptákova N; Kuthi L; Pivovarcikova K; Rogala J; Agaimy A; Hartmann A; Fraune C; Rychly B; Hurnik P; Durcansky D; Bonert M; Gakis G; Michal M; Hora M; Hes O
Mod Pathol; 2022 Mar; 35(3):344-351. PubMed ID: 34521993
[TBL] [Abstract][Full Text] [Related]
25. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
[TBL] [Abstract][Full Text] [Related]
26. Mechanistic Target of Rapamycin Kinase is a Common Convergent Pathway to Renal Neoplasia: A Contemporary Review.
Alruwaii ZI; Williamson SR; Al-Obaidy KI
Int J Surg Pathol; 2024 Jan; ():10668969231219653. PubMed ID: 38258297
[TBL] [Abstract][Full Text] [Related]
27. Lycopene in the prevention of renal cell cancer in the TSC2 mutant Eker rat model.
Sahin K; Cross B; Sahin N; Ciccone K; Suleiman S; Osunkoya AO; Master V; Harris W; Carthon B; Mohammad R; Bilir B; Wertz K; Moreno CS; Walker CL; Kucuk O
Arch Biochem Biophys; 2015 Apr; 572():36-39. PubMed ID: 25602702
[TBL] [Abstract][Full Text] [Related]
28. Kidney Tumors: New and Emerging Kidney Tumor Entities.
Siadat F; Mansoor M; Hes O; Trpkov K
Clin Lab Med; 2023 Jun; 43(2):275-298. PubMed ID: 37169446
[TBL] [Abstract][Full Text] [Related]
29. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
30. Xanthomatous Giant Cell Renal Cell Carcinoma: Another Morphologic Form of TSC -associated Renal Cell Carcinoma.
Argani P; Matoso A; Pallavajjalla A; Haley L; Tseh-Lin M; Ng J; Chow CW; Lotan T; Mehra R
Am J Surg Pathol; 2022 Nov; 46(11):1554-1561. PubMed ID: 35941720
[TBL] [Abstract][Full Text] [Related]
31. Kidney Tumors: New and Emerging Kidney Tumor Entities.
Siadat F; Mansoor M; Hes O; Trpkov K
Surg Pathol Clin; 2022 Dec; 15(4):713-728. PubMed ID: 36344185
[TBL] [Abstract][Full Text] [Related]
32. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1.
Morini A; Drossart T; Timsit MO; Sibony M; Vasiliu V; Gimenez-Roqueplo AP; Favier J; Badoual C; Mejean A; Burnichon N; Verkarre V
Mod Pathol; 2022 Mar; 35(3):352-360. PubMed ID: 34531523
[TBL] [Abstract][Full Text] [Related]
33. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT.
Ricci C; Ambrosi F; Franceschini T; Giunchi F; Grillini A; Franchini E; Grillini M; Schiavina R; Massari F; Mollica V; Tateo V; Bianchi FM; Bianchi L; Droghetti M; Maloberti T; Tallini G; Colecchia M; Acosta AM; Lobo J; Trpkov K; Fiorentino M; de Biase D
Virchows Arch; 2023 Nov; 483(5):687-698. PubMed ID: 37845471
[TBL] [Abstract][Full Text] [Related]
35. New insights in the new WHO classification of adult renal tumors.
Hes O; Michalová K; Pivovarčíková K
Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
[TBL] [Abstract][Full Text] [Related]
36. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
37. TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background.
Pivovarcikova K; Alaghehbandan R; Vanecek T; Ohashi R; Pitra T; Hes O
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203531
[TBL] [Abstract][Full Text] [Related]
38. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
[TBL] [Abstract][Full Text] [Related]
40. "Oncocytoid Renal Cell Carcinomas After Neuroblastoma" Represent TSC -mutated Eosinophilic Solid and Cystic Renal Cell Carcinomas : Association With Prior Childhood Malignancy and Multifocality With Therapeutic Implications.
Argani P; Medeiros LJ; Matoso A; Baraban E; Lotan T; Pawel BR; McKenney JK; Mehra R; Falzarano SM; Pallavajjalla A; Lin MT; Patel S; Rawwas J; Bendel AE; Gagan J; Palsgrove DN
Am J Surg Pathol; 2023 Dec; 47(12):1335-1348. PubMed ID: 37522346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
